W

bioLLM/wiki

LLM-Synthesized Biotech Database

Live

STAT5A

STAT5A

Overview

STAT5A is a member of the signal transducer and activator of transcription (STAT) family of transcription factors and a key component of the JAK/STAT pathway. Like other STAT proteins, STAT5A is activated downstream of cytokine receptors and growth factor signaling, where phosphorylation promotes dimerization, nuclear translocation, and regulation of gene expression. In biomedical research, STAT5A is closely associated with hematopoietic signaling, immune regulation, and oncogenic signaling programs.

Recent studies have continued to position STAT5A as an important signaling node in cancer and immunology. It is frequently discussed alongside related molecules such as JAK2, FLT3, AKT, ERK/MAPK1, TP53, transforming growth factor-beta, and anti-inflammatory cytokines, reflecting its role in integrating extracellular cues into transcriptional responses. Because STAT5A can support proliferation, survival, and lineage-specific immune functions, it is also being explored as both a mechanistic biomarker and a therapeutic target in drug-response studies.

Recent Publications Focus

Below is a summary of the newest research publications targeting STAT5A (sorted by publication date).

  • Targeting STAT5A in chronic myeloid leukemia and drug resistance: A study in Medical Oncology reported that CRISPR/Cas9-mediated targeting of STAT5A restored tyrosine kinase inhibitor sensitivity in resistant chronic myeloid leukemia cells. The authors described STAT5A as a principal downstream effector of BCR::ABL1 and emphasized its role as a transcriptional regulator implicated in the development of TKI resistance. This work positions STAT5A as a functional node in K-562-derived resistance models, including K562/Ima-Res and K562/Pon-Res systems, and supports the concept that suppressing STAT5A can reverse resistant phenotypes.

  • STAT5A in natural killer cell antitumor activity: In the Journal for Immunotherapy of Cancer, investigators showed that SMAD7 promotes natural killer cell antitumor activity through canonical TGF-β blockade and non-canonical transcriptional activation of STAT5A. This study links STAT5A to immune effector function and suggests that STAT5A activation can contribute to antitumor immunity in the context of transforming growth factor-beta signaling suppression.

  • STAT5 signaling in immune modulation by CDK8/CDK19 inhibition: A Blood study on primary immune thrombocytopenia found that CDK8/CDK19 inhibition rapidly augmented STAT5 phosphorylation and subsequent Foxp3 induction. Although the publication focused on broader immune homeostasis, it highlights STAT5A-associated signaling as part of the mechanism by which the intervention restored T-cell balance in a murine model of active ITP.

  • STAT5A and adaptive resistance in AML epigenetic therapy: In Signal Transduction and Targeted Therapy, researchers studying the LSD1 inhibitor DC551040 reported that key signaling members including STAT5, NF-κB, and AKT were involved in adaptive resistance. The study used AML-relevant systems and suggested that STAT5-family signaling remains a critical pathway to monitor when evaluating epigenetic therapies and combination strategies.

  • STAT5A as a therapeutic target in rheumatoid arthritis macrophages: A Cellular & Molecular Immunology paper on tofacitinib showed that the drug repaired inflammation and mitochondrial dysregulation in GM-CSF-reprogrammed rheumatoid arthritis macrophages by downregulating GM-CSFRα expression and inhibiting STAT5 signaling. This supports a role for STAT5A-linked signaling in inflammatory macrophage activation and in the response to JAK inhibition.

  • Non-canonical activation of STAT5A in NK-cell biology: Another Journal for Immunotherapy of Cancer study reported that SMAD7 drives NK-cell antitumor activity through non-canonical transcriptional activation of STAT5A, reinforcing the importance of STAT5A in immune surveillance and effector-cell programming.

  • CAR T-cell engineering with constitutively active STAT5: In Cancer Immunology Research, investigators engineered CAR T cells to express constitutively active STAT5 (caSTAT5; N642H) and compared its effects with constitutively active STAT3. The study used caSTAT5 as a functional tool to dissect transcription factor contributions to CAR T-cell behavior, underscoring the relevance of STAT5A/STAT5 signaling in adoptive cell therapy design.

  • STAT5 phosphorylation in T-cell homeostasis and cytokine signaling: A Blood study on CDK8/CDK19 inhibition in primary immune thrombocytopenia found that treatment rapidly increased STAT5 phosphorylation and induced Foxp3, linking STAT5 signaling to regulatory T-cell biology. This work connects STAT5A-associated signaling to immune tolerance and homeostatic control.

  • Raman-guided monitoring of ruxolitinib response in leukemia: A study in Spectrochimica Acta Part A used Raman spectroscopy combined with chemometric analysis and multivariate analysis to monitor the effect of ruxolitinib on acute lymphoblastic leukemia. The authors reported that ruxolitinib selectively reduced STAT5 phosphorylation in JAK2-mutant cells and produced distinct Raman spectral shifts, particularly in DNA- and protein-related bands. This provides a noninvasive analytical framework for tracking STAT5 pathway inhibition.

  • FLT3 inhibition and downstream STAT5 suppression in AML: In European Journal of Pharmacology, nintedanib was shown to be a potent FLT3 inhibitor with activity against FLT3-ITD and the gatekeeper F691L resistance mutation in acute myeloid leukemia. The drug suppressed FLT3 autophosphorylation and downstream STAT5, ERK, and AKT signaling, leading to cell-cycle arrest and apoptosis. This reinforces STAT5A as a downstream readout of FLT3-driven oncogenic signaling in AML cell lines such as MV4-11 and MOLM-13.

  • Trikine immunotherapeutics and engineered STAT signaling: A Science paper on Trikine immunotherapeutics described receptor-assembled cytokine combinations that coactivated phosphorylation of STAT5 and STAT3 in patterns distinct from natural cytokines. By using interleukin 2, interleukin 10, and interleukin 21 receptor assemblies, the study demonstrated that STAT5 signaling can be rewired from the cell surface, highlighting the plasticity of STAT5A-linked signaling in immune engineering.

  • FLT3-ITD inhibition by indolocarbazole glycoalkaloids: A European Journal of Medicinal Chemistry study identified novel staurosporine-type indolocarbazole glycoalkaloids as potent and selective FLT3-ITD inhibitors for acute myeloid leukemia. Mechanistic studies showed that compound 35 suppressed FLT3 phosphorylation and downstream STAT5, Akt, and Erk signaling, induced G2/M cell-cycle arrest, and triggered apoptosis in FLT3-ITD-positive AML cells. This further supports STAT5A as a key downstream effector in FLT3-driven leukemogenesis.

  • STAT5A in PD-1-targeted IL-15 mutein signaling: In JCI Insight, a PD-1-targeted IL-15 mutein was reported to activate STAT5 signaling in PD-1-positive lymphocytes and restore effector function in exhausted T cells. The study linked STAT5 activation to enhanced CD8+ and CD4+ T-cell activity in infection and cancer, showing how targeted cytokine delivery can harness STAT5A-associated pathways in anti-PD-1 therapy contexts.

  • STAT5A in acute lymphoblastic leukemia drug response: A Spectrochimica Acta Part A study using Raman spectroscopy and chemometric analysis found that ruxolitinib selectively reduced STAT5 phosphorylation in JAK2-mutant cells. The work connected pathway inhibition with measurable spectral changes, supporting STAT5A phosphorylation as a pharmacodynamic marker in leukemia models.

Result PMIDs

  • [PMID 42060360]
  • [PMID 41889033]
  • [PMID 41762803]
  • [PMID 42035942]
  • [PMID 41712697]

Target PMIDs

  • [PMID 41758968]
  • [PMID 41770851]
  • [PMID 42033509]
  • [PMID 41956539]
  • [PMID 41781698]
  • [PMID 41872160]
Content is generated using Large Language Models (LLMs) and may contain errors or hallucinations. Experts periodically review it to verify accuracy and maintain database integrity.